NeuroPace Inc
Close on Oct 19, 2026
- Market cap
- $435.51M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Nov 3, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | During market hours | $22.80M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | During market hours | $22.10M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 3, 2026 | During market hours | $26.60M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | During market hours | $27.40M | $-0.11 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | During market hours | $23.50M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | $22.50M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 4, 2025 | During market hours | $21.50M | $-0.18 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | During market hours | $21.10M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 11, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | full year 2026 | -$8.50M to -$7.50M | Raised |
| non-GAAP gross marginnon-GAAP | full year | 82% to 83% | Raised |
| non-GAAP operating expensesnon-GAAP | full year | $90.00M to $92.00M | Maintained |
| total revenue | full year 2026 | $99.50M to $101.50M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements NeuroPace filed with the SEC
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
Results of operations · EX-99 to Form 8-K
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized
Regulation FD disclosure · EX-99.1 to Form 8-K
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
Results of operations · EX-99 to Form 8-K
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
Results of operations · EX-99.1 to Form 8-K
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
NeuroPace Announces Strategic CFO Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
NeuroPace Secures Up to $75 Million in Debt Financing
Material agreement · Agreement terminated · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
NeuroPace Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
NeuroPace Provides Update on Tariff Status
Regulation FD disclosure · EX-99.1 to Form 8-K
NeuroPace Announces Refocusing of Product Portfolio
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
NeuroPace Issues 2025 Financial Guidance Targets
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides
Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K
NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
Results of operations · EX-99.1 to Form 8-K
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Disclaimer In addition to background and historical information, this
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
NeuroPace Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
NeuroPace Reports Fourth Quarter & Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
| 2 Disclaimer In addition to background and historical information,
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
NeuroPace Reports Third Quarter 2022 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
NeuroPace Reports Second Quarter 2022 Financial Results and Provides a Business Update
Material agreement · Results of operations · EX-99.1 to Form 8-K
NeuroPace Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
NeuroPace Reports Fourth Quarter & Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Revenue
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
| 2 Disclaimer In addition to background and historical information,
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
NeuroPace Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K